Literature DB >> 10720863

Course of calcium stone disease without treatment. What can we expect?

W L Strohmaier1.   

Abstract

OBJECTIVES: The knowledge of the natural history (i.e. the course of the disease without metaphylaxis is the base for establishing rational guidelines for metaphylaxis in urolithiasis.
METHODS: This review is based on a Medlinetrade mark Search (1966-1999) and the proceedings of the Bonn-Vienna and European symposia on urolithiasis. Only 31 references were sufficient for the purpose of this review.
RESULTS: In idiopathic calcium stone disease, stone frequency without metaphylaxis is 0.10-0.15 stones per patient per year. The average recurrence rate is 30-40%. Recurrence rate increases with age and observation time. Risk for recurrence is highest during the first 4 years after the first stone episode. More than 50% of all recurrent stone formers have only one recurrence during their lives. 10% of recurrent stone formers have more than 3 recurrences. Risk factors for recurrence are: male sex, multiple and lower calyx stones, early onset, familial history, complications after stone removal. Metabolic evaluation is a poor predictor of the risk for recurrence.
CONCLUSIONS: Renunciation of metaphylaxis is justified in first stone formers with idiopathic calcium oxalate and apatite stones. All patients, however, should be advised to increase their fluid intake.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10720863     DOI: 10.1159/000052367

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  29 in total

1.  Impact of hypoxia and hypercapnia on calcium oxalate toxicity in renal epithelial and interstitial cells.

Authors:  Yanwei Cao; Sreedhar Sagi; Axel Häcker; Annette Steidler; Peter Alken; Thomas Knoll
Journal:  Urol Res       Date:  2006-04-22

Review 2.  [Recurrence prevention of urolithiasis with respect to economic aspects].

Authors:  R Siener; N Laube; W L Strohmaier
Journal:  Urologe A       Date:  2011-10       Impact factor: 0.639

Review 3.  [Urinary calculi. Metabolism and diagnosis].

Authors:  R E Hautmann; M Straub
Journal:  Urologe A       Date:  2006-09       Impact factor: 0.639

4.  Stones: Impact of dose reduction on CT detection of urolithiasis.

Authors:  M Hammad Ather; Wasim A Memon
Journal:  Nat Rev Urol       Date:  2009-10       Impact factor: 14.432

5.  Should surgeons control fluoroscopy during urology procedures?

Authors:  Jeremy Setterfield; James Watterson; Mathew Playfair; Luke T Lavallée; Matthew Roberts; Brian Blew; J Stuart Oake
Journal:  Can Urol Assoc J       Date:  2016 Nov-Dec       Impact factor: 1.862

Review 6.  [Recurrence prevention of kidney stone disease].

Authors:  M Straub
Journal:  Urologe A       Date:  2011-10       Impact factor: 0.639

7.  Novel Risk Loci Identified in a Genome-Wide Association Study of Urolithiasis in a Japanese Population.

Authors:  Chizu Tanikawa; Yoichiro Kamatani; Chikashi Terao; Masayuki Usami; Atsushi Takahashi; Yukihide Momozawa; Kichiya Suzuki; Soichi Ogishima; Atsushi Shimizu; Mamoru Satoh; Keitaro Matsuo; Haruo Mikami; Mariko Naito; Kenji Wakai; Taiki Yamaji; Norie Sawada; Motoki Iwasaki; Shoichiro Tsugane; Kenjiro Kohri; Alan S L Yu; Takahiro Yasui; Yoshinori Murakami; Michiaki Kubo; Koichi Matsuda
Journal:  J Am Soc Nephrol       Date:  2019-04-11       Impact factor: 10.121

8.  Examination of the anti-oxidative effect in renal tubular cells and apoptosis by oxidative stress.

Authors:  Yasunori Itoh; Takahiro Yasui; Atsushi Okada; Keiichi Tozawa; Yutaro Hayashi; Kenjiro Kohri
Journal:  Urol Res       Date:  2005-08

9.  Genetic differences in C57BL/6 mouse substrains affect kidney crystal deposition.

Authors:  Masayuki Usami; Atsushi Okada; Kazumi Taguchi; Shuzo Hamamoto; Kenjiro Kohri; Takahiro Yasui
Journal:  Urolithiasis       Date:  2018-01-23       Impact factor: 3.436

10.  Family history in stone disease: how important is it for the onset of the disease and the incidence of recurrence?

Authors:  Hakan Hasbey Koyuncu; Faruk Yencilek; Bilal Eryildirim; Kemal Sarica
Journal:  Urol Res       Date:  2010-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.